{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:09:35Z","timestamp":1790982575145,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>There is a significant research gap in meta-analysis on the efficacy and safety of coronavirus disease 2019 (COVID-19) vaccines. This study analyzed the efficacy of COVID-19 vaccines. Published phase I, phase II, and phase III trials analyzing safety and immunogenicity and phase III randomized clinical trials evaluating the efficacy of COVID-19 vaccines were included. We searched MEDLINE, Scopus, and The Lancet for published articles evaluating the relative reduction in COVID-19 risk after vaccination. Selected literatures were published between December 15, 2019 and May 15, 2021 on the safety, efficacy, and immunogenicity of COVID-19 vaccines. This meta-analysis included studies that confirmed cases of COVID-19 using reverse transcriptase polymerase chain reaction. This study detected 8,926 eligible research articles published on COVID-19 vaccines. Of these, 25 studies fulfilled the inclusion criteria. Among the selected articles, 19 randomized clinical trials, 2 non-randomized clinical trials, and 3 observational studies were analyzed. Seven (28%) studies were included in the meta-analysis. The efficacy of the adenovirus vector vaccine was 73% (95% CI = 69\u201377) and that of the messenger RNA (mRNA) vaccine was 85% (95% CI = 82\u201388) in participants aged \u226518 years. There are no reports of clinical trials in participants aged under 16 years. The production of neutralizing antibodies against receptor-binding domains (RBDs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in &amp;gt;90% of the vaccinated samples was reported within 0\u201330 days of the first or the second dose of the vaccine. Pain at the injection site was the most common local symptom in people receiving mRNA vaccines (29%\u201385% of participants). Fever (0.2%\u201395%) was the most prevalent in people receiving adenovirus vector vaccines, and fatigue (8.4%\u201355%) was the most common side effect in people receiving the mRNA vaccines. Studies suggest that mRNA vaccines and adenovirus vector vaccines can provide moderate to high protection against COVID-19 infection in people over 18 years. Evidence of the long-term protection of the vaccines in people aged under 16 years against the multiple variants of COVID-19 are limited. This study will provide an integrated evaluation on the efficacy, safety, and immunogenicity of the COVID-19 vaccines.<\/jats:p>","DOI":"10.3389\/fimmu.2021.714170","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T15:49:08Z","timestamp":1634140148000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":207,"title":["Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Nadim","family":"Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid J.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsun Nahar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvra Kanti","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/01652176.2020.1727993","article-title":"Emerging Novel Coronavirus (2019-Ncov)\u2014Current Scenario, Evolutionary Perspective Based on Genome Analysis and Recent Developments","volume":"40","author":"Malik","year":"2020","journal-title":"Vet Q"},{"key":"B2","unstructured":"COVID-19 Map - Johns Hopkins Coronavirus Resource Center2021"},{"key":"B3","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard2021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/2Fpai.13298","article-title":"African American Children are at Higher Risk of COVID-19 Infection","volume":"31","author":"Bandi","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30589-2","article-title":"Risk of COVID-19 in Health-Care Workers in Denmark: An Observational Cohort Study","volume":"20","author":"Iversen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.005","article-title":"Clinical Features of COVID-19 in Elderly Patients: A Comparison With Young and Middle-Aged Patients","volume":"80","author":"Liu","year":"2020","journal-title":"J Infect"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.05.005","article-title":"Prevalence and Impact of Diabetes and Cardiovascular Disease on Clinical Outcome Among Patients With COVID-19 in Bangladesh","volume":"15","author":"Sharif","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06576","article-title":"Environmental Correlation and Epidemiologic Analysis of COVID-19 Pandemic in Ten Regions in Five Continents","volume":"7","author":"Sharif","year":"2021","journal-title":"Heliyon"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00352-y","article-title":"A Systematic Review of SARS-CoV-2 Vaccine Candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050467","article-title":"Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"9","author":"Pormohammad","year":"2021","journal-title":"Vaccines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-Generation Vaccine Platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat Mater"},{"key":"B12","unstructured":"DRAFT Landscape of COVID-19 Candidate Vaccines\u201420 March 20202020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"B14","unstructured":"SARS-CoV-2 Resources2021"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 Vaccine Against the B. 1.351 Variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J\u00a0Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and Immunogenicity of the ChAdOx1 Ncov-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind, Randomized Controlled Trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and Immunogenicity of an Rad26 and Rad5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomized Phase 1\/2 Studies From Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and Immunogenicity of ChAdOx1 Ncov-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomized, Controlled, Phase 2\/3 Trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomized, First-in-Human Trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J\u00a0Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-","article-title":"Phase I\/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomized, Double-Blind, Placebo-Controlled, Phase 1\/2 Trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01194-5","article-title":"T Cell and Antibody Responses Induced by a Single Dose of ChAdOx1 Ncov-19 (AZD1222) Vaccine in a Phase 1\/2 Clinical Trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomized Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 Ncov-19 (AZD1222) Vaccine Against SARS-CoV-2 Variant of Concern 202012\/01 (B. 1.1. 7): An Exploratory Analysis of a Randomized Controlled Trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E285","DOI":"10.1016\/S2666-5247(21)00082-3","article-title":"Serum Sample Neutralisation of BBIBP-CorV and ZF2001 Vaccines to SARS-CoV-2 501y. V2","volume":"2","author":"Huang","year":"2021","journal-title":"Lancet Microbe"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and Efficacy of an Rad26 and Rad5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomized Controlled Phase 3 Trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine Side-Effects and SARS-CoV-2 Infection After Vaccination in Users of the COVID Symptom Study App in the UK: A Prospective Observational Study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomized, Double-Blind, Placebo-Controlled, Phase 1\/2 Clinical Trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18\u201359 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 1\/2 Clinical Trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH 1 T Cell Responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa210154","article-title":"Safety and Efficacy of Single-Dose Ad26. COV2. S Vaccine Against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating Guidance for Reporting Systematic Reviews: Development of the PRISMA 2020 Statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The Methodological Quality Assessment Tools for Preclinical and Clinical Studies, Systematic Review and Meta-Analysis, and Clinical Practice Guideline: A Systematic Review","volume":"8","author":"Zeng","year":"2015","journal-title":"Evid Based Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J\u00a0Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and Immunogenicity of One Versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients With Cancer: Interim Analysis of a Prospective Observational Study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2139\/ssrn.3746259","article-title":"Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis","volume":"3746259","author":"Yuan","year":"2020","journal-title":"SSRN"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/2Fj.vaccine.2021.08.005","article-title":"Children are the Key to the Endgame: A Case for Routine Pediatric COVID Vaccination","volume":"39","author":"Schleiss","year":"2021","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and Effectiveness of Influenza Vaccines: A Systematic Review and Meta-Analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative Systematic Review and Meta-Analysis of Reactogenicity, Immunogenicity and Efficacy of Vaccines Against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11739-021-02685-0","article-title":"Deep Vein Thrombosis (DVT) Occurring Shortly After the Second Dose of mRNA SARS-CoV-2 Vaccine","volume":"9","author":"Carli","year":"2021","journal-title":"Intern Emerg Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 Vaccine\u2013Induced Immune Thrombotic Thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European Countries Suspend Use of Oxford-AstraZeneca Vaccine After Reports of Blood Clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.714170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T15:49:11Z","timestamp":1634140151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.714170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2021.714170"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.714170","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"article-number":"714170"}}